Oncotelic Subsidiary Sapu Nano Expands Phase 1b Clinical Trial for Sapu003 to Europe, Appoints Global CRO
Summary
Oncotelic Therapeutics' subsidiary, Sapu Nano, is expanding its Phase 1b clinical development program for Sapu003 into Europe and has appointed Global Clinical Trials (GCT) as the lead CRO. This move establishes the necessary infrastructure for future multinational Phase 3 development. This operational progress follows the company's recent Q1 2026 report, which included a substantially increased net loss and a 'going concern' warning. Advancing a clinical program internationally is a significant step for the company, potentially offsetting some financial concerns by demonstrating pipeline progress.
At the time of this announcement, OTLC was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $22.2M. The 52-week trading range was $0.02 to $0.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.